SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (date of earliest event reported) November 15, 1999
-----------------
OXIS INTERNATIONAL, INC.
- ----------------------------------------------------------------------------------------------------
Delaware 0-8092 94-1620407
- ----------------------------------------------------------------------------------------------------
(State or Other Jurisdiction of (Commission File Number) (IRS Employer Identification
Incorporation) Number)
6040 N. Cutter Circle, Suite 317 Portland, OR 97217-3935
- ----------------------------------------------------------------------------------------------------
(Address of Principal Executive Offices)
Registrant's telephone number, including area code. (503) 283-3911
-------------------------------------------------
____________________________________________________________________________________________________
(Former Name or Former Address if Changes Since Last Report)
Item 2. Acquisition or Disposition of Assets
--------------------------------------------
On November 15, 1999, OXIS International, Inc. ("OXIS") entered into an
Agreement with Enzon, Inc. ("Enzon") pursuant to which OXIS assigned to Enzon
the rights to its patents relating to polyalkylene glycols. OXIS retained a
non-exclusive perpetual paid-up license under these patents for PEG conjugated
superoxide dismutase. The Agreement is filed herewith as Exhibit 10.1.
In exchange for the assignment, OXIS received an up-front cash payment of
$600,000, and will receive an additional cash amount of $225,000 upon FDA
approval of the first U.S. product covered by these patents. Additionally,
Enzon will pay a royalty based on net sales of High Molecular Weight
polyalkylene glycol products it hereinafter chooses to develop and sell, which
are covered by these OXIS patents. This Agreement supercedes a July 1997 Non-
Exclusive License Agreement between these parties relating to these OXIS
patents.
2
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
------------------------------------------------------------------
(c) Exhibits
--------
Exhibit 10.1 Agreement dated October 15, 1999, by and between OXIS
International, Inc. and Enzon, Inc.
3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
November 24, 1999 OXIS INTERNATIONAL, INC.
(Registrant)
/s/ Jon S. Pitcher
-----------------------------
Chief Financial Officer and
Vice President
4
EXHIBIT INDEX
Page
Exhibit Number
- ------- ------
Exhibit 10.1 Agreement dated October 15, 1999, by and
between OXIS International, Inc. and Enzon, Inc. 6
5